These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 32410959)

  • 1. Positive Allosteric Modulation of CB
    Slivicki RA; Iyer V; Mali SS; Garai S; Thakur GA; Crystal JD; Hohmann AG
    Front Mol Neurosci; 2020; 13():54. PubMed ID: 32410959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Positive Allosteric Modulation of Cannabinoid Receptor Type 1 Suppresses Pathological Pain Without Producing Tolerance or Dependence.
    Slivicki RA; Xu Z; Kulkarni PM; Pertwee RG; Mackie K; Thakur GA; Hohmann AG
    Biol Psychiatry; 2018 Nov; 84(10):722-733. PubMed ID: 28823711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cannabinoid CB
    Iyer V; Slivicki RA; Thomaz AC; Crystal JD; Mackie K; Hohmann AG
    Eur J Pharmacol; 2020 Nov; 886():173544. PubMed ID: 32896549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Positive allosteric modulation of the cannabinoid type-1 receptor (CB1R) in periaqueductal gray (PAG) antagonizes anti-nociceptive and cellular effects of a mu-opioid receptor agonist in morphine-withdrawn rats.
    Datta U; Kelley LK; Middleton JW; Gilpin NW
    Psychopharmacology (Berl); 2020 Dec; 237(12):3729-3739. PubMed ID: 32857187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Negative allosteric modulation of CB
    Iyer V; Saberi SA; Pacheco R; Sizemore EF; Stockman S; Kulkarni A; Cantwell L; Thakur GA; Hohmann AG
    Neuropharmacology; 2024 Oct; 257():110052. PubMed ID: 38936657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Cannabinoid Receptor Type 1 Positive Allosteric Modulator ZCZ011 Attenuates Naloxone-Precipitated Diarrhea and Weight Loss in Oxycodone-Dependent Mice.
    Dodu JC; Moncayo RK; Damaj MI; Schlosburg JE; Akbarali HI; O'Brien LD; Kendall DA; Wu Z; Lu D; Lichtman AH
    J Pharmacol Exp Ther; 2022 Jan; 380(1):1-14. PubMed ID: 34625464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brain-Permeant and -Impermeant Inhibitors of Fatty Acid Amide Hydrolase Synergize with the Opioid Analgesic Morphine to Suppress Chemotherapy-Induced Neuropathic Nociception Without Enhancing Effects of Morphine on Gastrointestinal Transit.
    Slivicki RA; Saberi SA; Iyer V; Vemuri VK; Makriyannis A; Hohmann AG
    J Pharmacol Exp Ther; 2018 Dec; 367(3):551-563. PubMed ID: 30275151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Negative allosteric modulation of CB
    Iyer V; Rangel-Barajas C; Woodward TJ; Kulkarni A; Cantwell L; Crystal JD; Mackie K; Rebec GV; Thakur GA; Hohmann AG
    Pharmacol Res; 2022 Nov; 185():106474. PubMed ID: 36179954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Negative allosteric modulation of cannabinoid CB
    Iyer V; Saberi SA; Pacheco R; Sizemore EF; Stockman S; Kulkarni A; Cantwell L; Thakur GA; Hohmann AG
    bioRxiv; 2024 Jan; ():. PubMed ID: 38260598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cannabinoid CB2 Agonist AM1710 Differentially Suppresses Distinct Pathological Pain States and Attenuates Morphine Tolerance and Withdrawal.
    Li AL; Lin X; Dhopeshwarkar AS; Thomaz AC; Carey LM; Liu Y; Nikas SP; Makriyannis A; Mackie K; Hohmann AG
    Mol Pharmacol; 2019 Feb; 95(2):155-168. PubMed ID: 30504240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic attenuation of chronic pain using mu opioid and cannabinoid receptor 2 agonists.
    Grenald SA; Young MA; Wang Y; Ossipov MH; Ibrahim MM; Largent-Milnes TM; Vanderah TW
    Neuropharmacology; 2017 Apr; 116():59-70. PubMed ID: 28007501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The endocannabinoid hydrolysis inhibitor SA-57: Intrinsic antinociceptive effects, augmented morphine-induced antinociception, and attenuated heroin seeking behavior in mice.
    Wilkerson JL; Ghosh S; Mustafa M; Abdullah RA; Niphakis MJ; Cabrera R; Maldonado RL; Cravatt BF; Lichtman AH
    Neuropharmacology; 2017 Mar; 114():156-167. PubMed ID: 27890602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic and additive interactions of the cannabinoid agonist CP55,940 with mu opioid receptor and alpha2-adrenoceptor agonists in acute pain models in mice.
    Tham SM; Angus JA; Tudor EM; Wright CE
    Br J Pharmacol; 2005 Mar; 144(6):875-84. PubMed ID: 15778704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
    Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
    J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topical cannabinoid enhances topical morphine antinociception.
    Yesilyurt O; Dogrul A; Gul H; Seyrek M; Kusmez O; Ozkan Y; Yildiz O
    Pain; 2003 Sep; 105(1-2):303-8. PubMed ID: 14499448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intrathecal atipamezole augments the antinociceptive effect of morphine in rats.
    Lilius TO; Rauhala PV; Kambur O; Rossi SM; Väänänen AJ; Kalso EA
    Anesth Analg; 2012 Jun; 114(6):1353-8. PubMed ID: 22556211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sigma-1 receptor antagonism as opioid adjuvant strategy: enhancement of opioid antinociception without increasing adverse effects.
    Vidal-Torres A; de la Puente B; Rocasalbas M; Touriño C; Bura SA; Fernández-Pastor B; Romero L; Codony X; Zamanillo D; Buschmann H; Merlos M; Baeyens JM; Maldonado R; Vela JM
    Eur J Pharmacol; 2013 Jul; 711(1-3):63-72. PubMed ID: 23632394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolerance to the antinociceptive effects of chronic morphine requires c-Jun N-terminal kinase.
    Marcus DJ; Zee M; Hughes A; Yuill MB; Hohmann AG; Mackie K; Guindon J; Morgan DJ
    Mol Pain; 2015 Jun; 11():34. PubMed ID: 26065412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Selective Monoacylglycerol Lipase Inhibitor MJN110 Produces Opioid-Sparing Effects in a Mouse Neuropathic Pain Model.
    Wilkerson JL; Niphakis MJ; Grim TW; Mustafa MA; Abdullah RA; Poklis JL; Dewey WL; Akbarali H; Banks ML; Wise LE; Cravatt BF; Lichtman AH
    J Pharmacol Exp Ther; 2016 Apr; 357(1):145-56. PubMed ID: 26791602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of Gβγ-subunit signaling potentiates morphine-induced antinociception but not respiratory depression, constipation, locomotion, and reward.
    Hoot MR; Sypek EI; Reilley KJ; Carey AN; Bidlack JM; McLaughlin JP
    Behav Pharmacol; 2013 Apr; 24(2):144-52. PubMed ID: 23412114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.